Marathon Pharmaceuticals is one of the leading pharmaceutical company focused on drugs for people with rare diseases. This company was brought down to the market by the Northbrook, Illinois-based company developed and manufactured therapeutics. It employed 100 people in four global locations.
In the year of 2017, PTC Therapeutics acquired rights to Marathon Pharmaceuticals' drug Emflaza containing deflazacort for $140 million. It produced medicines for high-need, small people populations, including people with rare diseases as outlined by the U.S. Food and Drug Administration’s Orphan Drug Act.
This leading pharmaceutical company manufactures late-stage drugs, earned regulatory approvals, and then manufactured and commercialized medicines with input from patient advocacy groups. Marathon’s regulatory efforts. It is centered on gaining FDA approval of New Drug Applications (NDA) or Biologic License Applications (BLA).
Marathon Pharmaceuticals offers assistance for eligible people with financial hardship and helped them to secure other assistance through the National Organization of Rare Disorders (NORD) and similar patient support groups. This company distributed its products in North America also.
There are no products to list.